Bionano Genomics, Inc. (BNGO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Bionano Genomics, Inc. reported revenue of $28.51M, down 7.4% from the prior year. The company ran a net loss, with a net margin of -92.6%. It held $73.58M in total assets against $29.16M in total liabilities.
Key ratios (FY2025)
-116.9%
Operating margin
-92.6%
Net margin
-59.4%
Return on equity
-7.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.51M | $30.78M | $36.12M | $27.80M | $17.98M | $8.50M | $10.13M | $12.00M | — | — |
| Cost of Revenue | $15.32M | $30.40M | $26.55M | $21.86M | $14.11M | $5.73M | $6.77M | $8.71M | $6.03M | — |
| Operating Income | -$33.34M | -$103.98M | -$215.25M | -$131.70M | -$77.10M | -$38.55M | -$25.87M | -$20.42M | -$23.22M | — |
| Net Income | -$26.39M | -$112.02M | -$232.49M | -$132.60M | -$72.44M | -$41.11M | -$29.82M | -$18.50M | -$23.37M | — |
| EPS (Diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 | — | — | — | — | — |
| Total Assets | $73.58M | $76.67M | $214.40M | $307.50M | $377.10M | $60.45M | $30.21M | $24.80M | $10.15M | — |
| Total Liabilities | $29.16M | $41.30M | $118.25M | $58.10M | $39.98M | $25.37M | $26.59M | $14.67M | $17.36M | — |
| Shareholders' Equity | $44.42M | $35.38M | $96.16M | $249.40M | $337.12M | $35.08M | $3.61M | $10.14M | -$50.23M | -$27.26M |
| Cash & Equivalents | $2.99M | $9.17M | $17.95M | $5.09M | $24.57M | $38.45M | $17.31M | $16.52M | $1.02M | — |
| Operating Cash Flow | -$16.34M | -$68.92M | -$125.18M | -$124.82M | -$71.93M | -$38.31M | -$29.53M | -$19.94M | -$20.82M | — |
| Capital Expenditures | — | — | — | — | — | $0 | $61.1K | $331.7K | $1.02M | — |
| Shares Outstanding | 10.74M | 1.87M | 762.5K | 29.72M | 289.60M | 189.95M | 34.27M | 10.06M | 77.3K | — |